Breaking News Instant updates and real-time market news.

TTCF

Tattooed Chef

$15.68 /

-1.15 (-6.83%)

09:35
11/20/20
11/20
09:35
11/20/20
09:35

Tattooed Chef tells Bloomberg short report claims 'false' and 'misleading'

Tattooed Chef said in a statement emailed to Bloomberg that a short report published yesterday by Kerrisdale Capital includes claims that are "false" and "misleading." "The company is aware of a short seller that is manipulating the market, making false and misleading claims regarding the company, and will financially benefit from a decline in Tattooed Chef's stock price. Tattooed Chef remains committed to increasing shareholder value," the company stated to Bloomberg.

TTCF Tattooed Chef
$15.68 /

-1.15 (-6.83%)

11/17/20 Roth Capital
Tattooed Chef initiated with a Buy at Roth Capital

TODAY'S FREE FLY STORIES

On The Fly
Opening Day: Sports analytics company Sportradar drops in trading debut » 10:34
09/18/21
09/18
10:34
09/18/21
10:34
FORG

ForgeRock

$45.46 /

+8.86 (+24.21%)

, HZON

Horizon Acquisition Corp. II

$9.80 /

+0.04 (+0.41%)

, ACT

Enact Holdings

$20.01 /

-0.41 (-2.01%)

, ONON

On Holding

$38.95 /

+1.45 (+3.87%)

, DICE

Dice Therapeutics

$37.73 /

+1.93 (+5.39%)

, DH

Definitive Healthcare

$48.99 /

+1.87 (+3.97%)

, BROS

Dutch Bros

$43.56 /

-4.42 (-9.21%)

, TWKS

Thoughtworks

$34.06 /

+2.7 (+8.61%)

, PRCT

Procept BioRobotics

$40.03 /

+3.77 (+10.40%)

, KTTA

Pasithea Therapeutics

$3.14 /

-0.23 (-6.82%)

, SRAD

Sportradar

$27.01 /

+0.22 (+0.82%)

, RNXT

RenovoRx

$7.46 /

-0.45 (-5.69%)

, SQL

SeqLL

$3.91 /

+0.09 (+2.36%)

, DDI

DoubleDown

$17.50 /

+0.22 (+1.27%)

, QNIU

Qiniu

/

+

, CMSL

Camposol

/

+

, SPRK

Spark Education

/

+

, SCAN

Perspectum Group

/

+

, AUTH

Authentic Brands Group

$8.01 /

+ (+0.00%)

, ARBK

Argo Blockchain

/

+

, WRBY

Warby Parker

/

+

, TOST

Toast

/

+

, HLTH

Cue Health

/

+

, ALVU

Allvue

/

+

, BIRD

Allbirds

/

+

, GTLB

GitLab

/

+

, KETR

Keter

/

+

, AMZN

Amazon.com

$3,461.96 /

-25.76 (-0.74%)

, F

Ford

$13.56 /

+0.16 (+1.19%)

, BABA

Alibaba

$160.00 /

+3.74 (+2.39%)

, EZFL

EzFill

$4.57 /

-0.62 (-11.95%)

The Switzerland-based…

ShowHide Related Items >><<
RNXT RenovoRx
$7.46 /

-0.45 (-5.69%)

ONON On Holding
$38.95 /

+1.45 (+3.87%)

FORG ForgeRock
$45.46 /

+8.86 (+24.21%)

F Ford
$13.56 /

+0.16 (+1.19%)

DDI DoubleDown
$17.50 /

+0.22 (+1.27%)

BROS Dutch Bros
$43.56 /

-4.42 (-9.21%)

BABA Alibaba
$160.00 /

+3.74 (+2.39%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

AMZN Amazon.com
$3,461.96 /

-25.76 (-0.74%)

ALVU Allvue
/

+

FORG ForgeRock
$45.46 /

+8.86 (+24.21%)

HZON Horizon Acquisition Corp. II
$9.80 /

+0.04 (+0.41%)

ACT Enact Holdings
$20.01 /

-0.41 (-2.01%)

ONON On Holding
$38.95 /

+1.45 (+3.87%)

09/17/21 Citi
Deckers Brands portfolio being 'significantly undervalued,' says Citi
DICE Dice Therapeutics
$37.73 /

+1.93 (+5.39%)

DH Definitive Healthcare
$48.99 /

+1.87 (+3.97%)

BROS Dutch Bros
$43.56 /

-4.42 (-9.21%)

TWKS Thoughtworks
$34.06 /

+2.7 (+8.61%)

PRCT Procept BioRobotics
$40.03 /

+3.77 (+10.40%)

KTTA Pasithea Therapeutics
$3.14 /

-0.23 (-6.82%)

SRAD Sportradar
$27.01 /

+0.22 (+0.82%)

RNXT RenovoRx
$7.46 /

-0.45 (-5.69%)

SQL SeqLL
$3.91 /

+0.09 (+2.36%)

DDI DoubleDown
$17.50 /

+0.22 (+1.27%)

QNIU Qiniu
/

+

CMSL Camposol
/

+

SPRK Spark Education
/

+

SCAN Perspectum Group
/

+

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

ARBK Argo Blockchain
/

+

WRBY Warby Parker
/

+

TOST Toast
/

+

HLTH Cue Health
/

+

ALVU Allvue
/

+

BIRD Allbirds
/

+

GTLB GitLab
/

+

KETR Keter
/

+

AMZN Amazon.com
$3,461.96 /

-25.76 (-0.74%)

09/14/21 Evercore ISI
Amazon price target raised to $4,700 from $4,200 at Evercore ISI
09/13/21
Fly Intel: Top five analyst initiations
09/13/21 Goldman Sachs
Amazon.com initiated with a Buy at Goldman Sachs
09/10/21 BofA
Affirm price target raised to $119 from $82 at BofA
F Ford
$13.56 /

+0.16 (+1.19%)

09/08/21 Benchmark
Worst of chip shortage could be over for Ford, says Benchmark
07/16/21 BofA
Ford price target raised to $18 from $17 at BofA
06/29/21 UBS
Ford price target raised to $16 from $13 at UBS
06/22/21 Barclays
Ford price target raised to $17 from $15 at Barclays
BABA Alibaba
$160.00 /

+3.74 (+2.39%)

09/15/21 Stifel
Alibaba price target lowered to $210 from $260 at Stifel
09/06/21 KGI Securities
Alibaba initiated with a Neutral at KGI Securities
08/20/21 Erste Group
Alibaba downgraded to Sell from Hold at Erste Group
08/05/21 Susquehanna
Alibaba price target lowered to $310 from $350 at Susquehanna
EZFL EzFill
$4.57 /

-0.62 (-11.95%)

F Ford
$13.56 /

+0.16 (+1.19%)

BABA Alibaba
$160.00 /

+3.74 (+2.39%)

AMZN Amazon.com
$3,461.96 /

-25.76 (-0.74%)

  • 24
    Sep
  • 23
    Sep
  • 15
    Sep
  • 22
    Sep
  • 16
    Sep
  • 15
    Sep
  • 15
    Sep
  • 29
    Sep
  • 15
    Sep
  • 15
    Sep
  • 15
    Sep
  • 15
    Sep
  • 16
    Sep
  • 15
    Sep
  • 14
    Sep
  • 27
    Aug
  • 26
    Aug
  • 31
    Aug
  • 16
    Jul
  • 13
    May
SRAD Sportradar
$27.01 /

+0.22 (+0.82%)

HZON Horizon Acquisition Corp. II
$9.80 /

+0.04 (+0.41%)

F Ford
$13.56 /

+0.16 (+1.19%)

BABA Alibaba
$160.00 /

+3.74 (+2.39%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

AMZN Amazon.com
$3,461.96 /

-25.76 (-0.74%)

PRCT Procept BioRobotics
$40.03 /

+3.77 (+10.40%)

ONON On Holding
$38.95 /

+1.45 (+3.87%)

HZON Horizon Acquisition Corp. II
$9.80 /

+0.04 (+0.41%)

F Ford
$13.56 /

+0.16 (+1.19%)

BABA Alibaba
$160.00 /

+3.74 (+2.39%)

AMZN Amazon.com
$3,461.96 /

-25.76 (-0.74%)

HZON Horizon Acquisition Corp. II
$9.80 /

+0.04 (+0.41%)

F Ford
$13.56 /

+0.16 (+1.19%)

BABA Alibaba
$160.00 /

+3.74 (+2.39%)

AMZN Amazon.com
$3,461.96 /

-25.76 (-0.74%)

Periodicals
Selloff on Macau casino operations reviews 'a buying opportunity,' Barron's says » 10:07
09/18/21
09/18
10:07
09/18/21
10:07
WYNN

Wynn Resorts

$83.30 /

-1.095 (-1.30%)

, LVS

Las Vegas Sands

$38.17 /

+0.66 (+1.76%)

Wynn Resorts (WYNN) and…

Wynn Resorts (WYNN) and Las Vegas Sands (LVS) shares suffered sharp losses the past couple of days amid jitters that the Macau government will impose more onerous concession, or licensing, agreements when they expire next year, Lawrence Strauss writes in this week's edition of Barron's. The rout, however, could be setting up a buying opportunity for investors who are patient and have a bankroll to withstand the unlucky streak, some analysts say. Reference Link

ShowHide Related Items >><<
WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

LVS Las Vegas Sands
$38.17 /

+0.66 (+1.76%)

WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

09/17/21
Fly Intel: Top five analyst downgrades
09/17/21 Argus
Wynn Resorts downgraded to Hold from Buy at Argus
09/17/21 Argus
Wynn Resorts downgraded to Hold from Buy at Argus
09/16/21 JPMorgan
Wynn Resorts downgraded on Macau uncertainty at JPMorgan
LVS Las Vegas Sands
$38.17 /

+0.66 (+1.76%)

09/17/21 Jefferies
Jefferies downgrades Las Vegas Sands on 'growth uncertainty' in Macau
09/17/21 Jefferies
Las Vegas Sands downgraded to Hold from Buy at Jefferies
09/16/21 JPMorgan
JPMorgan downgrades Las Vegas Sands on Macau uncertainty
WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

LVS Las Vegas Sands
$38.17 /

+0.66 (+1.76%)

  • 09
    Feb
WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

LVS Las Vegas Sands
$38.17 /

+0.66 (+1.76%)

WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

LVS Las Vegas Sands
$38.17 /

+0.66 (+1.76%)

Periodicals
COVID vaccine could lift Sanofi stock, Barron's says » 10:04
09/18/21
09/18
10:04
09/18/21
10:04
SNY

Sanofi

$48.35 /

+0.14 (+0.29%)

, PFE

Pfizer

$43.89 /

-0.57 (-1.28%)

, AZN

AstraZeneca

$55.56 /

-1.04 (-1.84%)

, GSK

GlaxoSmithKline

$38.94 /

-0.16 (-0.41%)

Few Big Pharma companies…

Few Big Pharma companies have proved able to catch the early wave of COVID-19 vaccines and ride it to success. But Sanofi (SNY) is trying hard to show that there is a life after failure-or, as the company would prefer to put it, setback, Pierre Briancon writes in this week's edition of Barron's. While rivals Pfizer (PFE) and AstraZeneca (AZN) showed potential of cross-cooperation with smaller, nimbler partners in developing and producing vaccines against the new virus in record time, for Sanofi and partner GlaxoSmithKline (GSK), it looked more like a process of hits and misses, with a series of setbacks leading to a vaccine delay, the author notes. The jab is now in its Phase 3 trial, and Sanofi spokesman Nicolas Kressmann says the company has a good chance of producing its results "before the end of the last quarter at the earliest," which means that if everything goes according to plan, regulators the world over will then approve it for distribution within days. Reference Link

ShowHide Related Items >><<
SNY Sanofi
$48.35 /

+0.14 (+0.29%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

09/14/21 Mizuho
Kadmon downgraded to Neutral from Buy at Mizuho
09/10/21 UBS
Kadmon downgraded to Neutral from Buy at UBS
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/09/21 Benchmark
Sanofi deal for Kadmon reinforces Incyte thesis, says Benchmark
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

09/17/21 Evercore ISI
Innate Pharma price target raised to $10 from $6 at Evercore ISI
09/17/21 Morgan Stanley
AstraZeneca price target raised to 10,000 GBp from 9,800 GBp at Morgan Stanley
08/12/21 JPMorgan
AstraZeneca resumed with an Overweight at JPMorgan
GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
SNY Sanofi
$48.35 /

+0.14 (+0.29%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

Periodicals
iPhone 13 didn't surprise, Apple stock still might, Barron's says » 09:59
09/18/21
09/18
09:59
09/18/21
09:59
AAPL

Apple

$146.00 /

-2.84 (-1.91%)

On the surface, last…

On the surface, last week's edition of Apple 's annual fall product launch event was kind of a yawner, Eric Savitz writes in this week's edition of Barron's. But dig in a little, and you can find lots to chew on, he added. The biggest takeaway is that Apple's outlook is a little brighter than skeptics on the Street would have you believe, the author contends. Reference Link

ShowHide Related Items >><<
AAPL Apple
$146.00 /

-2.84 (-1.91%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

09/17/21 Jefferies
Snap Q3 revenue estimates too low, says Jefferies
09/15/21 Oppenheimer
Apple's iPhone 13 likely to attract upgraders, says Oppenheimer
09/15/21 Deutsche Bank
Apple iPhone changes 'more incremental than transformative,' says Deutsche Bank
09/15/21 Morgan Stanley
Improved iPhone affordability raises Morgan Stanley confidence in Apple growth
AAPL Apple
$146.00 /

-2.84 (-1.91%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

Periodicals
Good news not expected when Nike reports earnings, Barron's says » 09:56
09/18/21
09/18
09:56
09/18/21
09:56
NKE

Nike

$156.41 /

-1.21 (-0.77%)

Nike has a China…

Nike has a China problem-one that could come to the fore when it releases its earnings this coming Thursday, and investors should take caution heading into the call, Ben Levisohn writes in this week's edition of Barron's. Reference Link

ShowHide Related Items >><<
NKE Nike
$156.41 /

-1.21 (-0.77%)

NKE Nike
$156.41 /

-1.21 (-0.77%)

09/13/21
Fly Intel: Top five analyst downgrades
09/13/21 BTIG
BTIG downgrades Nike on 'severe supply chain disruptions' in Vietnam
09/13/21 BTIG
Nike downgraded to Neutral from Buy at BTIG
09/09/21 UBS
Nike more likely to rise than fall after Q1 results, says UBS
NKE Nike
$156.41 /

-1.21 (-0.77%)

NKE Nike
$156.41 /

-1.21 (-0.77%)

NKE Nike
$156.41 /

-1.21 (-0.77%)

NKE Nike
$156.41 /

-1.21 (-0.77%)

Periodicals
Merck, Pfizer stand to gain amid arrival of pills to battle COVID, Barron's says » 09:30
09/18/21
09/18
09:30
09/18/21
09:30
MRK

Merck

$71.70 /

-0.25 (-0.35%)

, PFE

Pfizer

$43.89 /

-0.57 (-1.28%)

, AVIR

Atea Pharmaceuticals

$26.23 /

-0.9 (-3.32%)

In the earliest days of…

In the earliest days of COVID-19 pandemic, investor and drug developers looked to antivirals to blunt the impact of the disease but didn't have much luck, with the only antiviral authorized by the Food and Drug Administration to date being Gilead's (GILD) Veklury, also known as remdesivir, Josh Nathan-Kazis writes in this week's edition of Barron's. But the next generation of COVID-19 antivirals are now on the way, and a pill to treat - or even prevent - COVID-19 could be available by the end of the year. Merck (MRK), Pfizer (PFE), and the biotech Atea Pharmaceuticals (AVIR) each expect late-stage data on an oral Covid-19 antiviral in the coming months. If the data are positive, the drugs provide a major opportunity for the companies-one that investors should not ignore, the author notes. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

AVIR Atea Pharmaceuticals
$26.23 /

-0.9 (-3.32%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley downgrades Merck to Equal Weight, awaits strategic action
09/07/21 Morgan Stanley
Merck downgraded to Equal Weight from Overweight at Morgan Stanley
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
AVIR Atea Pharmaceuticals
$26.23 /

-0.9 (-3.32%)

09/09/21 SVB Leerink
Atea Pharmaceuticals initiated with an Outperform at SVB Leerink
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
01/29/21 JPMorgan
Atea Pharmaceuticals price target raised to $66 from $45 at JPMorgan
11/24/20 Evercore ISI
Atea Pharmaceuticals initiated with an Outperform at Evercore ISI
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

  • 30
    Oct
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

AVIR Atea Pharmaceuticals
$26.23 /

-0.9 (-3.32%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

AVIR Atea Pharmaceuticals
$26.23 /

-0.9 (-3.32%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

Periodicals
Mining stocks offer cheap play on growth, Barron's says » 09:24
09/18/21
09/18
09:24
09/18/21
09:24
BHP

BHP Group

$55.53 /

-2.57 (-4.42%)

, RIO

Rio Tinto

$68.05 /

-2.1 (-2.99%)

, NGLOY

Anglo American

$18.06 /

-1.5899 (-8.09%)

, GLNCY

Glencore

$9.01 /

-0.17 (-1.85%)

, VALE

Vale

$16.30 /

-0.42 (-2.51%)

Big diversified mining…

Big diversified mining companies BHP Group (BHP), Rio Tinto (RIO), Anglo American (NGLOY), Glencore (GLNCY), and Vale (VALE) are in the best shape ever, Andrew Bary writes in this week's edition of Barron's. Their shares, however, trade cheaply amid worries that the good times in industrial commodities are ending. For investors willing to accept some risk, the Big Five miners offer a rich opportunity, the author argues. Reference Link

ShowHide Related Items >><<
VALE Vale
$16.30 /

-0.42 (-2.51%)

RIO Rio Tinto
$68.05 /

-2.1 (-2.99%)

GLNCY Glencore
$9.01 /

-0.17 (-1.85%)

BHP BHP Group
$55.53 /

-2.57 (-4.42%)

BHP BHP Group
$55.53 /

-2.57 (-4.42%)

09/14/21 Barclays
BHP Group downgraded to Equal Weight from Overweight at Barclays
08/18/21 RBC Capital
BHP Group price target lowered to 2,300 GBp from 2,400 GBp at RBC Capital
07/30/21 CLSA
Rio Tinto downgraded to Sell from Underperform at CLSA
07/08/21 Berenberg
BHP Group upgraded to Buy from Hold at Berenberg
RIO Rio Tinto
$68.05 /

-2.1 (-2.99%)

09/17/21 Morgan Stanley
Rio Tinto price target lowered to 5,410 GBp from 6,330 GBp at Morgan Stanley
09/17/21 UBS
Rio Tinto price target lowered to A$86 from A$102 at UBS
09/16/21 Deutsche Bank
Rio Tinto price target lowered to 6,000 GBp from 6,600 GBp at Deutsche Bank
09/14/21 Barclays
Rio Tinto price target lowered to 4,900 GBp from 6,000 GBp at Barclays
NGLOY Anglo American
$18.06 /

-1.5899 (-8.09%)

09/17/21 Morgan Stanley
Anglo American downgraded to Equal Weight from Overweight at Morgan Stanley
09/17/21 UBS
Anglo American downgraded to Sell from Neutral at UBS
09/16/21 Deutsche Bank
Anglo American price target lowered to 3,600 GBp at Deutsche Bank
09/14/21 Barclays
Anglo American price target lowered to 3,600 GBp from 3,700 GBp at Barclays
GLNCY Glencore
$9.01 /

-0.17 (-1.85%)

09/17/21 Morgan Stanley
Glencore upgraded to Overweight from Equal Weight at Morgan Stanley
09/16/21 RBC Capital
Glencore price target raised to 400 GBp from 360 GBp at RBC Capital
09/16/21 Deutsche Bank
Glencore price target raised to 440 GBp from 420 GBp at Deutsche Bank
09/16/21 RBC Capital
Glencore price target raised to 400 GBp from 360 GBp at RBC Capital
VALE Vale
$16.30 /

-0.42 (-2.51%)

09/17/21 UBS
Vale downgraded to Sell from Buy at UBS
07/15/21 HSBC
Vale price target raised to $27 from $25 at HSBC
07/12/21 Scotiabank
Vale price target raised to $26 from $24 at Scotiabank
07/02/21 RBC Capital
Vale price target lowered to $27 from $29 at RBC Capital
VALE Vale
$16.30 /

-0.42 (-2.51%)

VALE Vale
$16.30 /

-0.42 (-2.51%)

RIO Rio Tinto
$68.05 /

-2.1 (-2.99%)

GLNCY Glencore
$9.01 /

-0.17 (-1.85%)

BHP BHP Group
$55.53 /

-2.57 (-4.42%)

GLNCY Glencore
$9.01 /

-0.17 (-1.85%)

BHP BHP Group
$55.53 /

-2.57 (-4.42%)

VALE Vale
$16.30 /

-0.42 (-2.51%)

RIO Rio Tinto
$68.05 /

-2.1 (-2.99%)

BHP BHP Group
$55.53 /

-2.57 (-4.42%)

Conference/Events
European Society for Medical Oncology to hold a virtual meeting » 04:55
09/18/21
09/18
04:55
09/18/21
04:55
ABBV

AbbVie

$107.75 /

-0.33 (-0.31%)

, AYLA

Ayala Pharmaceuticals

$12.25 /

-0.01 (-0.08%)

, DCPH

Deciphera

$33.08 /

+1.45 (+4.58%)

, GMAB

Genmab

$43.10 /

+0.845 (+2.00%)

, LPTX

Leap Therapeutics

$2.65 /

+0.13 (+5.16%)

, ORIC

Oric Pharmaceuticals

$25.20 /

+0.99 (+4.09%)

, SYNH

Syneos Health

$94.34 /

+0.55 (+0.59%)

, BGNE

BeiGene

$403.60 /

+18.32 (+4.75%)

, BMY

Bristol-Myers

$61.32 /

+0.1 (+0.16%)

, BYSI

BeyondSpring

$23.00 /

+0.47 (+2.09%)

, CALA

Calithera Biosciences

$2.25 /

+0.2 (+9.76%)

, GILD

Gilead

$71.61 /

+0.34 (+0.48%)

, GH

Guardant Health

$132.01 /

+5.01 (+3.94%)

, LLY

Eli Lilly

$230.17 /

-0.78 (-0.34%)

, IPSEY

Ipsen

$23.92 /

-0.395 (-1.62%)

, EXAS

Exact Sciences

$108.29 /

+5.47 (+5.32%)

, IDYA

Ideaya Biosciences

$26.90 /

+0.9 (+3.46%)

, GSK

GlaxoSmithKline

$38.94 /

-0.16 (-0.41%)

, RHHBY

Roche

$46.07 /

-0.75 (-1.60%)

, REGN

Regeneron

$651.38 /

-2.3 (-0.35%)

, PFE

Pfizer

$43.89 /

-0.57 (-1.28%)

, TAK

Takeda Pharmaceutical

$17.16 /

-0.045 (-0.26%)

, TMO

Thermo Fisher

$596.98 /

+36.11 (+6.44%)

, TCRR

TCR2 Therapeutics

$10.00 /

-5.715 (-36.38%)

, VERU

Veru

$8.94 /

+0.17 (+1.94%)

, VBLT

VBL Therapeutics

$2.32 /

-0.035 (-1.49%)

, VTRS

Viatris

$13.57 /

-0.13 (-0.95%)

, NVS

Novartis

$83.49 /

-0.88 (-1.04%)

ESMO 2021 Virtual…

ESMO 2021 Virtual Congress will be held on September 16-21. Webcast Link

ShowHide Related Items >><<
VTRS Viatris
$13.57 /

-0.13 (-0.95%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

VBLT VBL Therapeutics
$2.32 /

-0.035 (-1.49%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

IPSEY Ipsen
$23.92 /

-0.395 (-1.62%)

IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

GMAB Genmab
$43.10 /

+0.845 (+2.00%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

GH Guardant Health
$132.01 /

+5.01 (+3.94%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

DCPH Deciphera
$33.08 /

+1.45 (+4.58%)

CALA Calithera Biosciences
$2.25 /

+0.2 (+9.76%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

AYLA Ayala Pharmaceuticals
$12.25 /

-0.01 (-0.08%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
09/08/21 JPMorgan
AbbVie offers 'best risk/reward story in the group,' says JPMorgan
09/07/21 Morgan Stanley
Morgan Stanley cuts Vertex Pharmaceuticals to Underweight amid AbbVie overhang
AYLA Ayala Pharmaceuticals
$12.25 /

-0.01 (-0.08%)

07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with Buy, $29 target at Ladenburg
07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with a Buy at Ladenburg
12/07/20
Fly Intel: Top five analyst initiations
12/07/20 Roth Capital
Ayala Pharmaceuticals initiated with a Buy at Roth Capital
DCPH Deciphera
$33.08 /

+1.45 (+4.58%)

08/04/21 H.C. Wainwright
Deciphera price target lowered to $70 from $75 at H.C. Wainwright
05/05/21 Barclays
Deciphera price target lowered to $65 from $70 at Barclays
05/05/21 H.C. Wainwright
Deciphera price target lowered to $75 from $80 at H.C. Wainwright
05/05/21 Piper Sandler
Deciphera price target lowered to $60 from $75 at Piper Sandler
GMAB Genmab
$43.10 /

+0.845 (+2.00%)

09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Genmab to Underweight amid high investor expectations
LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

09/16/21 Piper Sandler
Leap data show 'very favorable early signal,' says Piper Sandler
09/13/21 Raymond James
Leap Therapeutics price target raised to $4 from $3 at Raymond James
09/13/21 Piper Sandler
Leap combo sees 'strong' early response rate, says Piper Sandler
06/03/21 Baird
Leap Therapeutics transferred with Outperform at Baird
ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy after tumor data at Citi
07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

08/04/21 Credit Suisse
Syneos Health assumed with an Outperform at Credit Suisse
07/13/21 Barclays
Syneos Health price target raised to $102 from $90 at Barclays
06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

09/08/21 Baird
BeyondSpring initiated with an Outperform at Baird
08/04/21 Evercore ISI
BeyondSpring price target raised to $95 from $30 at Evercore ISI
08/04/21 William Blair
BeyondSpring may have new standard of care in lung cancer, says William Blair
08/04/21 H.C. Wainwright
Wainwright upgrades BeyondSpring with $100 target on lung cancer data
CALA Calithera Biosciences
$2.25 /

+0.2 (+9.76%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
GILD Gilead
$71.61 /

+0.34 (+0.48%)

07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
GH Guardant Health
$132.01 /

+5.01 (+3.94%)

08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Guardant Health initiated with a Market Perform at Raymond James
LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
IPSEY Ipsen
$23.92 /

-0.395 (-1.62%)

08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
08/03/21 Morgan Stanley
Ipsen price target raised to EUR 92 from EUR 85 at Morgan Stanley
08/02/21 Societe Generale
Ipsen price target raised to EUR 101 from EUR 90 at Societe Generale
07/30/21 Credit Suisse
Ipsen price target raised to EUR 90 from EUR 75 at Credit Suisse
EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/15/21 Canaccord
Exact Sciences progress in MRD space a positive, says Canaccord
09/01/21 Baird
UnitedHealth update to CRC screening coverage not a surprise, says Baird
IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

06/03/21 Baird
Ideaya Biosciences assumed with an Outperform at Baird
04/22/21 Roth Capital
Ideaya Biosciences price target raised to $38 from $31 at Roth Capital
04/19/21 H.C. Wainwright
Ideaya Biosciences price target raised to $35 from $29 at H.C. Wainwright
04/16/21 Roth Capital
Ideaya Biosciences price target raised to $31 from $23 at Roth Capital
GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
RHHBY Roche
$46.07 /

-0.75 (-1.60%)

09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
REGN Regeneron
$651.38 /

-2.3 (-0.35%)

09/15/21 Cantor Fitzgerald
Regeneron price target raised to $700 from $670 at Cantor Fitzgerald
09/15/21 H.C. Wainwright
Regeneron price target raised to $831 from $787 at H.C. Wainwright
09/15/21 Piper Sandler
Regeneron price target raised to $690 from $675 at Piper Sandler
09/09/21
Fly Intel: Top five analyst initiations
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

08/03/21 Piper Sandler
Arcturus strength attributable to large pharma's interest in mRNA, says Piper
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

08/04/21 Credit Suisse
Thermo Fisher assumed with an Outperform at Credit Suisse
08/04/21 Argus
Thermo Fisher price target raised to $600 from $530 at Argus
07/29/21 Cowen
Thermo Fisher price target raised to $560 from $525 at Cowen
07/29/21 BTIG
Thermo Fisher price target raised to $610 from $590 at BTIG
TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

09/17/21 Wedbush
TCR2 Therapeutics downgraded to Neutral from Outperform at Wedbush
08/06/21 BMO Capital
TCR2 Therapeutics price target lowered to $44 from $53 at BMO Capital
06/24/21 Goldman Sachs
TCR2 Therapeutics initiated with a Buy at Goldman Sachs
06/11/21 BMO Capital
TCR2 Therapeutics coverage transferred at BMO Capital
VERU Veru
$8.94 /

+0.17 (+1.94%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VBLT VBL Therapeutics
$2.32 /

-0.035 (-1.49%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
VTRS Viatris
$13.57 /

-0.13 (-0.95%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
NVS Novartis
$83.49 /

-0.88 (-1.04%)

09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
VTRS Viatris
$13.57 /

-0.13 (-0.95%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

VBLT VBL Therapeutics
$2.32 /

-0.035 (-1.49%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

GH Guardant Health
$132.01 /

+5.01 (+3.94%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

DCPH Deciphera
$33.08 /

+1.45 (+4.58%)

CALA Calithera Biosciences
$2.25 /

+0.2 (+9.76%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

AYLA Ayala Pharmaceuticals
$12.25 /

-0.01 (-0.08%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

  • 08
    Jul
  • 03
    Jun
  • 04
    May
  • 09
    Apr
  • 01
    Mar
  • 18
    Feb
  • 20
    Jan
  • 02
    Dec
  • 02
    Dec
  • 19
    Nov
  • 13
    Nov
  • 07
    Oct
TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

GMAB Genmab
$43.10 /

+0.845 (+2.00%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

GH Guardant Health
$132.01 /

+5.01 (+3.94%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

VTRS Viatris
$13.57 /

-0.13 (-0.95%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

Conference/Events
Truist to hold a virtual bus tour » 04:55
09/18/21
09/18
04:55
09/18/21
04:55
ATVI

Activision Blizzard

$79.61 /

+0.3 (+0.38%)

, EA

Electronic Arts

$133.92 /

-1.93 (-1.42%)

, MGNI

Magnite

$29.21 /

-0.275 (-0.93%)

, PLTK

Playtika

$26.92 /

-1.55 (-5.44%)

, RBLX

Roblox

$80.88 /

-0.62 (-0.76%)

, ROKU

Roku

$324.19 /

+0.96 (+0.30%)

, VZIO

Vizio

$19.09 /

+0.76 (+4.15%)

, ZNGA

Zynga

$8.00 /

+0.015 (+0.19%)

Digital…

Digital Entertainment/Digital Marketing Virtual Bus Tour will be held on September 13-21.

ShowHide Related Items >><<
ZNGA Zynga
$8.00 /

+0.015 (+0.19%)

VZIO Vizio
$19.09 /

+0.76 (+4.15%)

ROKU Roku
$324.19 /

+0.96 (+0.30%)

RBLX Roblox
$80.88 /

-0.62 (-0.76%)

PLTK Playtika
$26.92 /

-1.55 (-5.44%)

MGNI Magnite
$29.21 /

-0.275 (-0.93%)

EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

09/15/21 KeyBanc
EA's delay of Battlefield 2042 slight positive for Activision, says KeyBanc
09/15/21 Benchmark
EA shares reacting negatively to Battlefield 2042 delay rumors, says Benchmark
09/15/21 Truist
Battlefield 2042 delay would be 'modest negative' for EA, says Truist
09/13/21 JPMorgan
Activision should be bought on China regulation concerns, says JPMorgan
EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

09/15/21 Raymond James
Delay of EA's Battlefield 2042 likely a 'mild negative,' says Raymond James
MGNI Magnite
$29.21 /

-0.275 (-0.93%)

09/16/21 Susquehanna
Magnite upbeat analyst reaffirms positive thesis, says Susquehanna
08/31/21 Macquarie
Macquarie starts 'SSP leader' Magnite at Outperform
08/31/21 Macquarie
Magnite initiated with an Outperform at Macquarie
08/09/21 RBC Capital
Magnite assumed with an Outperform at RBC Capital
PLTK Playtika
$26.92 /

-1.55 (-5.44%)

09/10/21 Wedbush
Wedbush says Apple injunction could boost earnings for mobile game makers
09/10/21 Baird
Apple ruling could be positive for mobile game publishers, says Baird
08/05/21 Cowen
Playtika valuation remains extremely attractive, says Cowen
06/30/21 Morgan Stanley
Morgan Stanley double downgrades overvalued AppLovin to Underweight
RBLX Roblox
$80.88 /

-0.62 (-0.76%)

09/15/21 Benchmark
Benchmark reiterates Sell rating on Roblox after 'weak' August indicators
09/15/21 Truist
Roblox key performance indicators for August 'solid,' says Truist
09/10/21 Truist
Apple will likely appeal ruling in Epic case, says Truist
08/31/21 Jefferies
China crackdown 'more serious' for Roblox than U.S. publishers, says Jefferies
ROKU Roku
$324.19 /

+0.96 (+0.30%)

09/13/21 Stephens
Recent Apple TV+ news positive for Roku, says Stephens
09/09/21 Stephens
Premium prices of Amazon TVs reduces risk for Roku, says Stephens
09/09/21 KeyBanc
New Amazon Fire TVs 'incremental positive' for Roku, says KeyBanc
09/09/21 JPMorgan
Vizio added as new best idea in SMID-cap U.S. Internet at JPMorgan
VZIO Vizio
$19.09 /

+0.76 (+4.15%)

09/14/21
Fly Intel: Top five analyst initiations
09/14/21 Stephens
Stephens starts Vizio at Overweight with $27 price target
09/13/21 Stephens
Vizio initiated with an Overweight at Stephens
ZNGA Zynga
$8.00 /

+0.015 (+0.19%)

ZNGA Zynga
$8.00 /

+0.015 (+0.19%)

VZIO Vizio
$19.09 /

+0.76 (+4.15%)

ROKU Roku
$324.19 /

+0.96 (+0.30%)

RBLX Roblox
$80.88 /

-0.62 (-0.76%)

PLTK Playtika
$26.92 /

-1.55 (-5.44%)

MGNI Magnite
$29.21 /

-0.275 (-0.93%)

EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

  • 25
    Mar
  • 15
    Jan
ROKU Roku
$324.19 /

+0.96 (+0.30%)

RBLX Roblox
$80.88 /

-0.62 (-0.76%)

EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

ZNGA Zynga
$8.00 /

+0.015 (+0.19%)

VZIO Vizio
$19.09 /

+0.76 (+4.15%)

ROKU Roku
$324.19 /

+0.96 (+0.30%)

RBLX Roblox
$80.88 /

-0.62 (-0.76%)

PLTK Playtika
$26.92 /

-1.55 (-5.44%)

MGNI Magnite
$29.21 /

-0.275 (-0.93%)

EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

ZNGA Zynga
$8.00 /

+0.015 (+0.19%)

VZIO Vizio
$19.09 /

+0.76 (+4.15%)

ROKU Roku
$324.19 /

+0.96 (+0.30%)

RBLX Roblox
$80.88 /

-0.62 (-0.76%)

MGNI Magnite
$29.21 /

-0.275 (-0.93%)

EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

Periodicals
Pioneer Natural launches sale of assets in Delaware basin of Texas, Reuters says » 18:40
09/17/21
09/17
18:40
09/17/21
18:40
PXD

Pioneer Natural

$157.03 /

+0.04 (+0.03%)

Pioneer Natural Resources…

Pioneer Natural Resources has put its assets in the Delaware basin of Texas up for sale, looking to secure more than $2B for the properties, Reuters' Arathy Nair, David French, and Shariq Khan report, citing two sources familiar with the matter. Reference Link

ShowHide Related Items >><<
PXD Pioneer Natural
$157.03 /

+0.04 (+0.03%)

PXD Pioneer Natural
$157.03 /

+0.04 (+0.03%)

09/09/21
Fly Intel: Top five analyst upgrades
09/09/21 Goldman Sachs
Pioneer Natural upgraded to Conviction Buy from Buy at Goldman Sachs
07/22/21 Piper Sandler
Pioneer Natural price target raised to $218 from $216 at Piper Sandler
07/15/21 Mizuho
Pioneer Natural price target raised to $231 from $224 at Mizuho
PXD Pioneer Natural
$157.03 /

+0.04 (+0.03%)

  • 11
    May
PXD Pioneer Natural
$157.03 /

+0.04 (+0.03%)

PXD Pioneer Natural
$157.03 /

+0.04 (+0.03%)

PXD Pioneer Natural
$157.03 /

+0.04 (+0.03%)

Hot Stocks
Astellas Pharma, Pfizer: XTANDI improved OS in Phase 3 ARCHES study » 18:09
09/17/21
09/17
18:09
09/17/21
18:09
ALPMY

Astellas Pharma

$17.08 /

-0.14 (-0.81%)

, PFE

Pfizer

$43.89 /

-0.57 (-1.28%)

Astellas Pharma (ALPMY)…

Astellas Pharma (ALPMY) and Pfizer (PFE) announced ahead of the European Society for Medical Oncology Congress 2021 that XTANDI improved overall survival in the ARCHES study in men with metastatic hormone-sensitive prostate cancer. The Phase 3, randomized, double-blind, placebo-controlled trial compared XTANDI plus androgen deprivation therapy versus placebo plus ADT in men with mHSPC and OS was a key secondary endpoint. In the study, XTANDI plus ADT reduced the risk of death by 34% compared to placebo plus ADT. Median OS, which represents the time from randomization to death due to any cause, was not reached in either treatment group. The safety profile in both study arms was consistent with findings from the primary analysis.

ShowHide Related Items >><<
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

ALPMY Astellas Pharma
$17.08 /

-0.14 (-0.81%)

ALPMY Astellas Pharma
$17.08 /

-0.14 (-0.81%)

06/29/21 Jefferies
Astellas Pharma downgraded to Hold from Buy at Jefferies
10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

Hot Stocks
Crocs director Bickley sells 5,000 common shares » 17:52
09/17/21
09/17
17:52
09/17/21
17:52
CROX

Crocs

$155.31 /

-2.39 (-1.52%)

In a regulatory filing,…

In a regulatory filing, Crocs director Ian Bickley disclosed the sale of 5,000 common shares of the company on September 16 at a price of $156.47 per share.

ShowHide Related Items >><<
CROX Crocs
$155.31 /

-2.39 (-1.52%)

CROX Crocs
$155.31 /

-2.39 (-1.52%)

09/15/21 Monness Crespi
Crocs price target raised to $180 from $160 at Monness Crespi
09/15/21 B. Riley
Crocs price target raised to $174 from $152 at B. Riley
09/15/21 Baird
Crocs price target raised to $215 from $160 at Baird
09/15/21 Loop Capital
Crocs price target raised to $180 from $150 at Loop Capital
CROX Crocs
$155.31 /

-2.39 (-1.52%)

CROX Crocs
$155.31 /

-2.39 (-1.52%)

CROX Crocs
$155.31 /

-2.39 (-1.52%)

CROX Crocs
$155.31 /

-2.39 (-1.52%)

Hot Stocks
NTSB to conduct safety investigation of fatal Tesla Model 3 crash in Florida » 17:48
09/17/21
09/17
17:48
09/17/21
17:48
TSLA

Tesla

$759.92 /

+2.995 (+0.40%)

The NTSB said that, in…

The NTSB said that, in coordination with City of Coral Gables Police Department, it is sending three investigators to conduct a safety investigation of the fatal Sept. 13, 2021, vehicle crash involving a Tesla Model 3 that departed the roadway and collided with a tree in Coral Gables, Florida. Reference Link

ShowHide Related Items >><<
TSLA Tesla
$759.92 /

+2.995 (+0.40%)

TSLA Tesla
$759.92 /

+2.995 (+0.40%)

09/17/21 Morgan Stanley
520 mile EPA range 'an important milestone' for Lucid, says Morgan Stanley
09/17/21 Wedbush
Tesla EV demand story just starting to play out, says Wedbush
09/15/21 BofA
BofA calls Lucid the 'Tesla/Ferrari of new EV automakers,' starts at Buy
09/10/21 Craig-Hallum
VIA Optronics price target lowered to $14 from $18 at Craig-Hallum
TSLA Tesla
$759.92 /

+2.995 (+0.40%)

TSLA Tesla
$759.92 /

+2.995 (+0.40%)

TSLA Tesla
$759.92 /

+2.995 (+0.40%)

TSLA Tesla
$759.92 /

+2.995 (+0.40%)

Conference/Events
Angion Biomedica to host research and development virtual day » 17:38
09/17/21
09/17
17:38
09/17/21
17:38
ANGN

Angion Biomedica

$10.57 /

-0.38 (-3.47%)

Research and Development…

Research and Development Virtual Day to be held on September 20 at 10 am. Webcast Link

ShowHide Related Items >><<
ANGN Angion Biomedica
$10.57 /

-0.38 (-3.47%)

ANGN Angion Biomedica
$10.57 /

-0.38 (-3.47%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Cowen
Angion Biomedica initiated with an Outperform at Cowen
03/02/21 Oppenheimer
Angion Biomedica initiated with an Outperform at Oppenheimer
03/02/21 Stifel
Angion Biomedica initiated with a Buy at Stifel
ANGN Angion Biomedica
$10.57 /

-0.38 (-3.47%)

  • 05
    Feb
ANGN Angion Biomedica
$10.57 /

-0.38 (-3.47%)

Hot Stocks
Azek exec Ochoa sells 20,000 class A shares » 17:37
09/17/21
09/17
17:37
09/17/21
17:37
AZEK

Azek

$38.56 /

+0.495 (+1.30%)

In a regulatory filing,…

In a regulatory filing, Azek Residential Segment President Joe Ochoa disclosed the sale of 20,000 class A common shares of the company on September 17 at a price of $38.67 per share.

ShowHide Related Items >><<
AZEK Azek
$38.56 /

+0.495 (+1.30%)

AZEK Azek
$38.56 /

+0.495 (+1.30%)

05/14/21 Baird
Azek price weakness a buying opportunity, says Baird
05/05/21 JPMorgan
Azek initiated with a Neutral at JPMorgan
04/13/21 Wedbush
Wedbush starts Azek with Outperform, $52 price target
04/12/21 Wedbush
Azek initiated with an Outperform at Wedbush
AZEK Azek
$38.56 /

+0.495 (+1.30%)

  • 27
    May
  • 22
    Jan
AZEK Azek
$38.56 /

+0.495 (+1.30%)

Syndicate
Greenidge Generation files to sell 3.5M shares of Class A common for holders  17:35
09/17/21
09/17
17:35
09/17/21
17:35
GREE

Greenidge Generation

$39.25 /

-4.35 (-9.98%)

 
Hot Stocks
Rolls-Royce awarded $194M Army contract » 17:17
09/17/21
09/17
17:17
09/17/21
17:17
RYCEY

Rolls-Royce

$1.49 /

+0.02 (+1.36%)

Rolls-Royce was awarded a…

Rolls-Royce was awarded a $194M firm-fixed-price contract for the acquisition of Namer Armored Personnel Carrier Power Packs Less Transmissions. Bids were solicited via the internet with one received. Work will be performed in Novi, Michigan, with an estimated completion date of December 31. FY20 Foreign Military Sales funds in the amount of $194M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

ShowHide Related Items >><<
RYCEY Rolls-Royce
$1.49 /

+0.02 (+1.36%)

RYCEY Rolls-Royce
$1.49 /

+0.02 (+1.36%)

08/17/21 JPMorgan
Rolls-Royce price target raised to 130 GBp from 105 GBp at JPMorgan
08/09/21 Deutsche Bank
Rolls-Royce price target raised to 116 GBp from 113 GBp at Deutsche Bank
08/06/21 Societe Generale
Rolls-Royce price target raised to 100 GBp from 95 GBp at Societe Generale
07/09/21 Jefferies
Rolls-Royce coverage transferred at Jefferies
RYCEY Rolls-Royce
$1.49 /

+0.02 (+1.36%)

RYCEY Rolls-Royce
$1.49 /

+0.02 (+1.36%)

Hot Stocks
Abbott awarded $119.51M Defense Logistics Agency contract » 17:14
09/17/21
09/17
17:14
09/17/21
17:14
ABT

Abbott

$126.80 /

-0.65 (-0.51%)

Abbott was awarded a…

Abbott was awarded a maximum $119.51M indefinite-delivery/indefinite-quantity contract for over-the-counter antigen test kits. This was a competitive acquisition with three responses received. This is a one-year contract with no option periods. Location of performance is all 50 states, with a September 14, 2022, ordering period end date. Primary customer is the Department of Health and Human Services. Type of appropriation is FY21 through FY22 defense working capital funds. The contracting activity is the Defense Logistics Agency Troop Support.

ShowHide Related Items >><<
ABT Abbott
$126.80 /

-0.65 (-0.51%)

ABT Abbott
$126.80 /

-0.65 (-0.51%)

09/17/21 Raymond James
U.S. contract awards 'major wins' for Quidel, OraSure, says Raymond James
08/31/21 BTIG
Abbott price target raised to $136 from $126 at BTIG
08/31/21 Barclays
Abbott's Amulet could become 'needle mover,' says Barclays
08/30/21 Piper Sandler
Boston Scientific's Watchman still well positioned, says Piper Sandler
ABT Abbott
$126.80 /

-0.65 (-0.51%)

ABT Abbott
$126.80 /

-0.65 (-0.51%)

ABT Abbott
$126.80 /

-0.65 (-0.51%)

ABT Abbott
$126.80 /

-0.65 (-0.51%)

Hot Stocks
Quidel awarded $710.57M Defense Logistics Agency contract » 17:12
09/17/21
09/17
17:12
09/17/21
17:12
QDEL

Quidel

$153.43 /

+8.93 (+6.18%)

Quidel has been awarded a…

Quidel has been awarded a maximum $710.57M indefinite-delivery/indefinite-quantity contract for over-the-counter antigen test kits. This was a competitive acquisition with three responses received. This is a one-year contract with no option periods. Location of performance is all 50 states, with a September 14, 2022, ordering period end date. Primary customer is the Department of Health and Human Services. Type of appropriation is FY21 through FY22 defense working capital funds. The contracting activity is the Defense Logistics Agency Troop Support.

ShowHide Related Items >><<
QDEL Quidel
$153.43 /

+8.93 (+6.18%)

QDEL Quidel
$153.43 /

+8.93 (+6.18%)

09/17/21 Raymond James
U.S. contract awards 'major wins' for Quidel, OraSure, says Raymond James
07/26/21 Piper Sandler
Quidel agreement with Beckman removes overhang, says Piper Sandler
07/19/21 Raymond James
Quidel contract with Delaware could increase materially, says Raymond James
07/19/21 Raymond James
Quidel contact with Delaware could increase materially, says Raymond James
QDEL Quidel
$153.43 /

+8.93 (+6.18%)

QDEL Quidel
$153.43 /

+8.93 (+6.18%)

QDEL Quidel
$153.43 /

+8.93 (+6.18%)

Hot Stocks
Boeing awarded $1.62B Navy contract » 17:10
09/17/21
09/17
17:10
09/17/21
17:10
BA

Boeing

$213.37 /

+0.05 (+0.02%)

Boeing has been awarded a…

Boeing has been awarded a $1.62B indefinite-delivery/indefinite-quantity contract for missile guidance repair. This contract will repair the Minuteman III Intercontinental Ballistic Missile, or ICBM, missile guidance set. Work will be performed in Newark, Ohio, and is expected to be completed by September 27, 2039. This award is the result of a sole-source acquisition. FY21 operation and maintenance funds in the amount of $32.49M are being obligated at the time of award. The Air Force Nuclear Weapons Center is the contracting activity.

ShowHide Related Items >><<
BA Boeing
$213.37 /

+0.05 (+0.02%)

BA Boeing
$213.37 /

+0.05 (+0.02%)

09/15/21 Susquehanna
Boeing upcoming catalysts should move shares higher, says Susquehanna
09/07/21 UBS
Boeing price target lowered to $290 from $310 at UBS
09/07/21 Baird
Boeing delivery expectations may be too high, says Baird
09/01/21 Susquehanna
Boeing delivery estimates lowered due to continued suspension, says Susquehanna
BA Boeing
$213.37 /

+0.05 (+0.02%)

BA Boeing
$213.37 /

+0.05 (+0.02%)

BA Boeing
$213.37 /

+0.05 (+0.02%)

BA Boeing
$213.37 /

+0.05 (+0.02%)

Hot Stocks
Oscar Health CEO acquires 57,300 class A shares » 17:08
09/17/21
09/17
17:08
09/17/21
17:08
OSCR

Oscar Health

$17.50 /

+0.02 (+0.11%)

In a regulatory filing,…

In a regulatory filing, Oscar Health CEO Mario Schlosser disclosed the purchase of 57,300 class A common shares of the company on September 16 at a price of $17.5308 per share.

ShowHide Related Items >><<
OSCR Oscar Health
$17.50 /

+0.02 (+0.11%)

OSCR Oscar Health
$17.50 /

+0.02 (+0.11%)

09/09/21 Cowen
Oscar Health initiated with a Market Perform at Cowen
08/04/21 Morgan Stanley
Morgan Stanley upgrades Bright Health to Overweight following underperformance
03/29/21 Wells Fargo
Oscar Health initiated with an Overweight at Wells Fargo
03/29/21
Fly Intel: Top five analyst initiations
OSCR Oscar Health
$17.50 /

+0.02 (+0.11%)

  • 03
    Mar
OSCR Oscar Health
$17.50 /

+0.02 (+0.11%)

Syndicate
PBF Logistics files automatic mixed securities shelf  17:07
09/17/21
09/17
17:07
09/17/21
17:07
PBFX

PBF Logistics

$12.20 /

-0.17 (-1.37%)

 
ShowHide Related Items >><<
PBFX PBF Logistics
$12.20 /

-0.17 (-1.37%)

07/29/21 R.F. Lafferty
PBF Logistics price target lowered to $16 after earnings at R.F. Lafferty
02/17/21 Citi
PBF Logistics price target raised to $12 from $8.50 at Citi
PBFX PBF Logistics
$12.20 /

-0.17 (-1.37%)

Syndicate
Humacyte files to sell 90.07M shares of common stock for holders  17:02
09/17/21
09/17
17:02
09/17/21
17:02
HUMA

Humacyte

$14.25 /

+0.09 (+0.64%)

 
ShowHide Related Items >><<
HUMA Humacyte
$14.25 /

+0.09 (+0.64%)

HUMA Humacyte
$14.25 /

+0.09 (+0.64%)

09/16/21
Fly Intel: Top five analyst initiations
09/16/21 Piper Sandler
Humacyte initiated with an Overweight at Piper Sandler
04/09/21 Lake Street
Lake Street starts Alpha Healthcare Acquisition at Buy ahead of Humacyte closing
HUMA Humacyte
$14.25 /

+0.09 (+0.64%)

Syndicate
Alkaline Water files to sell 9.51M shares of common stock for holders  17:01
09/17/21
09/17
17:01
09/17/21
17:01
WTER

Alkaline Water

$1.63 /

+0.045 (+2.84%)

 
ShowHide Related Items >><<
WTER Alkaline Water
$1.63 /

+0.045 (+2.84%)

WTER Alkaline Water
$1.63 /

+0.045 (+2.84%)

07/07/21
Fly Intel: Top five analyst downgrades
07/07/21 Canaccord
Canaccord downgrades Alkaline Water to Sell, says rally overdone
07/06/21 Canaccord
Alkaline Water downgraded to Sell from Hold at Canaccord
WTER Alkaline Water
$1.63 /

+0.045 (+2.84%)

WTER Alkaline Water
$1.63 /

+0.045 (+2.84%)

Syndicate
ShiftPixy files to sell 15.42M shares of common stock for holders  16:50
09/17/21
09/17
16:50
09/17/21
16:50
PIXY

ShiftPixy

$1.24 /

-0.02 (-1.59%)

 
ShowHide Related Items >><<
PIXY ShiftPixy
$1.24 /

-0.02 (-1.59%)

PIXY ShiftPixy
$1.24 /

-0.02 (-1.59%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.